Billy W. Loo
A5016420174- Lung Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Radiation Therapy and Dosimetry
- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Effects of Radiation Exposure
- Radiation Dose and Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Atomic and Subatomic Physics Research
- Cancer Immunotherapy and Biomarkers
- Advanced X-ray and CT Imaging
- Cancer, Hypoxia, and Metabolism
- Medical Imaging and Pathology Studies
- RNA modifications and cancer
- Radiation Detection and Scintillator Technologies
- Pleural and Pulmonary Diseases
- Cancer Diagnosis and Treatment
- Management of metastatic bone disease
- Ultrasound and Hyperthermia Applications
- Neuroendocrine Tumor Research Advances
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Stanford University
2016-2025
Stanford Cancer Institute
2014-2024
Cancer Institute (WIA)
2013-2024
Vanderbilt-Ingram Cancer Center
2024
Cancer Prevention Institute of California
2013-2023
Stanford Medicine
2007-2023
Georgia Institute of Technology
2023
University of California, Irvine
2021
Beverly Hospital
2021
Radiation Oncology Associates
2021
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies metastatic NSCLC, because therapeutic recommendations are rapidly changing disease. For example, new were added atezolizumab, ceritinib, osimertinib, pembrolizumab 2017 updates.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management patients with NSCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. Patients metastatic lung cancer who are eligible targeted therapies or immunotherapies now surviving longer. This selection from the NSCLC focuses on actionable mutations.
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates in immunotherapy. For the 2020 update, systemic therapy regimens have been categorized using a new preference stratification system; certain are now recommended as "preferred interventions," whereas others either "other interventions" or "useful under circumstances."
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization adjuvant therapies. Here, we apply personalized profiling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III 54 healthy adults. In 94% evaluable experiencing recurrence, ctDNA was detectable in the first posttreatment blood sample, indicating reliable...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates to the regarding targeted therapies, immunotherapies, and their respective biomarkers.
These NCCN Guidelines Insights focus on recent updates to the 2015 for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it important test tumor tissue from determine whether they alterations that make them candidates therapies. describe different testing methods currently available determining 2 most commonly actionable alterations, notably anaplastic lymphoma kinase (ALK) gene...
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates to the targeted therapy and immunotherapy sections in Guidelines. For 2018 update, a new section biomarkers was added.
These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was subject a major update in 2013 Clinical Practice Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The updates and discuss new greater detail.
These NCCN Guidelines Insights focus on recent updates in the 2016 for Non–Small Cell Lung Cancer (NSCLC; Versions 1–4). will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, patients with metastatic NSCLC. For update, panel recommends immune checkpoint inhibitors preferred agents (in absence of contraindications) second-line beyond (subsequent) therapy NSCLC (both squamous nonsquamous histologies). Nivolumab pembrolizumab are based improved overall survival rates,...
Most patients with non–small cell lung cancer (NSCLC) are diagnosed advanced cancer. These guidelines only include information about stage IV NSCLC. Patients widespread metastatic disease (stage IV) candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify before initiating aggressive treatment, thus sparing these from unnecessary futile If discovered during surgery, then extensive surgery often aborted. Decisions treatment should be based on...
<h3>Importance</h3> Stereotactic body radiation therapy (SBRT) has become a standard treatment for patients with medically inoperable early-stage lung cancer. However, its effectiveness in suitable surgery is unclear. <h3>Objective</h3> To evaluate whether noninvasive SBRT delivered on an outpatient basis can safely eradicate cancer and cure selected operable cancer, obviating the need surgical resection. <h3>Design, Setting, Participants</h3> Single-arm phase 2 NRG Oncology Radiation...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management patients with SCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. This selection the journal focuses on metastatic (known as extensive-stage) which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms prolong survival most extensive-stage disease. Smoking cessation counseling intervention...
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations management of disease in patients with NSCLC. These Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options eligible resectable
Abstract Lung squamous cell carcinoma (LSCC) pathogenesis remains incompletely understood, and biomarkers predicting treatment response remain lacking. Here, we describe novel murine LSCC models driven by loss of Trp53 Keap1, both which are frequently mutated in human LSCCs. Homozygous inactivation Keap1 or promoted airway basal stem (ABSC) self-renewal, suggesting that mutations these genes lead to expansion mutant clones. Deletion ABSCs, but not more differentiated tracheal cells, produced...
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple types, but whether further can improve outcomes patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 consolidation immune checkpoint inhibition (CICI). Patients undetectable after CRT had excellent or not they received CICI. Among such...
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These Insights focus on recent updates to the SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For 2018 update, new sections were added “Signs Symptoms SCLC” “Principles Pathologic Review.”
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance relapse, and subsequent treatment. panel has updated list recommended targeted therapies based on recent FDA approvals clinical data. This selection from NSCLC focuses advanced or metastatic actionable molecular biomarkers.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on principles of radiation therapy (RT), which include following: (1) general early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, normal tissue dose constraints advanced/palliative RT; (3) RT simulation, planning, delivery. Treatment recommendations should be made by a multidisciplinary team, including...
Abstract Radiation therapy is the most effective cytotoxic for localized tumors. However, normal tissue toxicity limits radiation dose and curative potential of when treating larger target volumes. In particular, highly radiosensitive intestine use patients with intra-abdominal metastatic ovarian cancer, total abdominal irradiation (TAI) was used as an postsurgical adjuvant in management metastases. TAI fell out favor due to high intestine. Here we utilized innovative preclinical platform...